Abstract
Our previous studies demonstrated that Ganoderma lucidum polysaccharides (Gl-PS) exhibit potent immunomodulating effects. Immunomodulation plays an important role in hematopoiesis. To investigate the possible mechanism by which Gl-PS promote myelopoiesis during myelosuppression induced by cyclophosphamide, mice were injected intraperitoneally (i.p.) once daily with 2.5 mg/kg of Gl-PS for 10 days and were treated i.p. once daily with cyclophosphamide (100 mg/kg) on days 2 through 4. In the present study in vivo and in vitro, we find that Gl-PS selectively bind to bone marrow stromal cells, stimulate the secretion of hematopoietic growth factors, and enhance the clonogenic activities of hematopoietic and stromal cells to promote hematopoiesis in myelosuppressed mice.
Highlights
Ganoderma lucidum is a fungus of the family Polyporaceae that is regarded by Chinese people as the “miraculous king of herbs” and has attained a reputation in the East as a beneficial herbal substance
The results of the present study demonstrate that GlPS (2.5 mg/kg) promote myelopoiesis in vivo in myelosuppressed www.frontiersin.org addition, an increase in stem cell factor (SCF) levels was observed in Ganoderma lucidum polysaccharides (Gl-PS)–BMSCM (Table 1)
Gl-PS injection increased the levels of IL-1β, IL-6, granulocyte colony-stimulating factor (G-CSF), and TNF-α, which were undetectable in normal sera, and IFN-γ in sera derived from myelosuppressed mice on day 11 (Table 2)
Summary
Ganoderma lucidum (known in China as Lingzhi and in Japan as Reishi) is a fungus of the family Polyporaceae that is regarded by Chinese people as the “miraculous king of herbs” and has attained a reputation in the East as a beneficial herbal substance. G. lucidum exhibits therapeutic efficacy in treating cancer, insomnia, chronic bronchitis, hepatitis, and leukopenia. Polysaccharides are one of the primary components of G. lucidum. Numerous studies have confirmed the immunoregulatory activities of Ganoderma lucidum polysaccharides (Gl-PS; Lin, 2005; Zhu and Lin, 2006; Zhao et al, 2010). Cyclophosphamide (Cy), a widely employed alkylating agent and a major constituent of combination chemotherapy regimens; it causes myelosuppression, which limits chemotherapy’s dose intensification and precludes the administration of optimal treatments for cancer patients (Bear, 1986)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call